Potent predictive CpG signature for temozolomide response in non-glioma-CpG island methylator phenotype glioblastomas with methylated MGMT promoter

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J. Clin. 70(4), 299–312 (2020).
  MedlineGoogle Scholar
• 2. Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: a paradigm shift in glioblastoma. Neuro Oncol. 24(5), 669–682 (2022).
  MedlineGoogle Scholar
• 3. Gupta T, Talukdar R, Kannan S, Dasgupta A, Chatterjee A, Patil V. Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: updated systematic review and meta-analysis. Neurooncol. Pract. 9(5), 354–363 (2022).
  MedlineGoogle Scholar
• 4. Rao V, Kumar G, Vibhavari R et al. Temozolomide resistance: a multifarious review on mechanisms beyond O-6-methylguanine-DNA methyltransferase. CNS Neurol. Disord. Drug Targets doi: 10.2174/1871527321666220404180944 (2022) (Epub ahead of print).
  MedlineGoogle Scholar
• 5. Di Nunno V, Franceschi E, Tosoni A et al. Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. Expert Rev. Anticancer Ther. 20(9), 785–795 (2020).
  MedlineGoogle Scholar
• 6. Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim. Biophys. Acta Rev. Cancer 1876(2), 188616 (2021).
  Medline CASGoogle Scholar
• 7. Cheng W, Ren X, Cai J et al. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Oncotarget 6(30), 29285–29295 (2015).
  MedlineGoogle Scholar
• 8. Wang W, Zhang L, Wang Z et al. A three-gene signature for prognosis in patients with MGMT promoter-methylated glioblastoma. Oncotarget 7(43), 69991–69999 (2016).
  MedlineGoogle Scholar
• 9. Brandner S, McAleenan A, Kelly C et al. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a cochrane systematic review. Neuro Oncol. 23(9), 1457–1469 (2021).
  Medline CASGoogle Scholar
• 10. Fan W, Wang D, Li G et al. A novel chemokine-based signature for prediction of prognosis and therapeutic response in glioma. CNS Neurosci. Ther. 28(12), 2090–2103 (2022).
  MedlineGoogle Scholar
• 11. Chen B, Zhou X, Yang L et al. Glioma stem cell signature predicts the prognosis and the response to tumor treating fields treatment. CNS Neurosci. Ther. 28(12), 2148–2162 (2022).
  Medline CASGoogle Scholar
• 12. Yu H, Zhang D, Lian M. Identification of an epigenetic prognostic signature for patients with lower-grade gliomas. CNS Neurosci. Ther. 27(4), 470–483 (2021).
  Medline CASGoogle Scholar
• 13. Ahmadpour S, Taghavi T, Sheida A, Tamehri ZS, Hamblin MR, Mirzaei H. Effects of microRNAs and long non-coding RNAs on chemotherapy response in glioma. Epigenomics 14(9), 549–563 (2022).
  CASGoogle Scholar
• 14. Issa JP. DNA methylation as a clinical marker in oncology. J. Clin. Oncol. 30(20), 2566–2568 (2012). •• Provides essential evidence on DNA methylation as ideal biomarker candidate.
  Medline CASGoogle Scholar
• 15. Galbraith K, Snuderl M. DNA methylation as a diagnostic tool. Acta Neuropathol. Commun. 10(1), 71 (2022).
  Medline CASGoogle Scholar
• 16. Yin A, Shang Z, Etcheverry A et al. Integrative analysis identifies an immune-relevant epigenetic signature for prognostication of non-G-CIMP glioblastomas. Oncoimmunology 10(1), 1902071 (2021).
  MedlineGoogle Scholar
• 17. Yin AA, Lu N, Etcheverry A et al. A novel prognostic six-CpG signature in glioblastomas. CNS Neurosci. Ther. 24(3), 167–177 (2018).
  Medline CASGoogle Scholar
• 18. Li B, Wang J, Liu F et al. A novel pseudogene methylation signature to predict temozolomide outcome in non-G-CIMP glioblastomas. J. Oncol. 2022, 6345160 (2022).
  MedlineGoogle Scholar
• 19. Malta TM, De Souza CF, Sabedot TS et al. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. Neuro Oncol. 20(5), 608–620 (2018).
  Medline CASGoogle Scholar
• 20. Noushmehr H, Weisenberger DJ, Diefes K et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17(5), 510–522 (2010). •• Comprehensive multi-omics analysis of the non-glioma-CpG island methylator phenotype (G-CIMP) glioblastoma (GBM) subtype by The Cancer Genome Atlas research network.
  Medline CASGoogle Scholar
• 21. Bady P, Sciuscio D, Diserens AC et al. MGMT methylation analysis of glioblastoma on the Infinium methylation beadchip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 124(4), 547–560 (2012). • Provided an approach to define a clinically relevant MGMT methylation status of GBM using high-throughput Illumina methylation microarray data.
  Medline CASGoogle Scholar
• 22. Wiestler B, Claus R, Hartlieb SA et al. Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol. 15(8), 1017–1026 (2013).
  Medline CASGoogle Scholar
• 23. Brennan CW, Verhaak RG, McKenna A et al. The somatic genomic landscape of glioblastoma. Cell 155(2), 462–477 (2013). •• Provides a comprehensive multi-omics analysis of GBM by The Cancer Genome Atlas research network.
  Medline CASGoogle Scholar
• 24. Etcheverry A, Aubry M, De Tayrac M et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics 11, 701 (2010).
  Medline CASGoogle Scholar
• 25. Lai RK, Chen Y, Guan X et al. Genome-wide methylation analyses in glioblastoma multiforme. PLOS ONE 9(2), e89376 (2014).
  MedlineGoogle Scholar
• 26. Kurscheid S, Bady P, Sciuscio D et al. Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma. Genome Biol. 16, 16 (2015).
  MedlineGoogle Scholar
• 27. Horvath S, Garagnani P, Bacalini MG et al. Accelerated epigenetic aging in Down syndrome. Aging Cell 14(3), 491–495 (2015). • Provided a DNA methylation dataset of non-tumor brains using high-throughput Illumina methylation microarray data.
  Medline CASGoogle Scholar
• 28. Du P, Zhang X, Huang CC et al. Comparison of beta-value and m-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11, 587 (2010).
  Medline CASGoogle Scholar
• 29. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8(1), 118–127 (2007).
  MedlineGoogle Scholar
• 30. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. Genepattern 2.0. Nat. Genet. 38(5), 500–501 (2006).
  Medline CASGoogle Scholar
• 31. Barbie DA, Tamayo P, Boehm JS et al. Systematic RNA interference reveals that oncogenic kRAS-driven cancers require TBK1. Nature 462(7269), 108–112 (2009).
  Medline CASGoogle Scholar
• 32. Subramanian A, Tamayo P, Mootha VK et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102(43), 15545–15550 (2005).
  Medline CASGoogle Scholar
• 33. Gould J, Getz G, Monti S, Reich M, Mesirov JP. Comparative gene marker selection suite. Bioinformatics 22(15), 1924–1925 (2006).
  Medline CASGoogle Scholar
• 34. Charoentong P, Finotello F, Angelova M et al. Pan-cancer immunogenomic analyses reveal genotype–immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 18(1), 248–262 (2017).
  Medline CASGoogle Scholar
• 35. Wu B, Miao Y, Bai Y et al. Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLOS ONE 7(4), e34588 (2012).
  Medline CASGoogle Scholar
• 36. Chen J, Tong X, Han M et al. Cost–effectiveness of short-course radiation plus temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States. Front. Pharmacol. 12, 743979 (2021).
  Medline CASGoogle Scholar
• 37. Loong HH, Wong C, Leung L et al. Cost–effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. Cost Eff. Resour. Alloc. 18, 2 (2020).
  MedlineGoogle Scholar
• 38. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997–1003 (2005).
  Medline CASGoogle Scholar
• 39. Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis. PLOS ONE 8(9), e74242 (2013).
  Medline CASGoogle Scholar
• 40. Yin AA, Zhang LH, Cheng JX et al. The predictive but not prognostic value of MGMT promoter methylation status in elderly glioblastoma patients: a meta-analysis. PLOS ONE 9(1), e85102 (2014).
  MedlineGoogle Scholar
• 41. Yin A, Etcheverry A, He Y et al. Integrative analysis of novel hypomethylation and gene expression signatures in glioblastomas. Oncotarget 8(52), 89607–89619 (2017). • Our previous multi-omics analysis on GBMs.
  MedlineGoogle Scholar
• 42. Roessler J, Ammerpohl O, Gutwein J et al. Quantitative cross-validation and content analysis of the 450 k DNA methylation array from Illumina, Inc. BMC Res. Notes 5, 210 (2012).
  Medline CASGoogle Scholar
• 43. Yin AA, He YL, Etcheverry A et al. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Clin. Epigenetics 11(1), 76 (2019). • Our previous genome-wide DNA methylation study on predicting temozolomide response for non-G-CIMP GBMs.
  MedlineGoogle Scholar